SCHEMBL2732863

SCHEMBL2732863

CCCCC#Cc1cccc2c1C(=O)N(c1ccccc1)C2=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.52
ALOX15 P16050 1/20 0.52
MAPK1 P28482 1/20 0.52
HSPA1A P0DMV8 1/20 0.49
PABPC1 P11940 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
APEX1 P27695 1/20 0.41
CYP2C19 P33261 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
PGR P06401 1/20 0.41
ALDH1A1 P00352 2/20 0.40
POLB P06746 1/20 0.40
MEN1 O00255 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2726528 0.95 HSD17B10 (0.50) HSD17B10ALOX15MAPK1HSPA1APABPC1
SCHEMBL2726989 0.76 HSPA1A (0.54) HSD17B10ALOX15MAPK1HSPA1APABPC1
SCHEMBL7675911 0.74 HSPA1A (0.54) HSD17B10ALOX15MAPK1HSPA1APABPC1
SCHEMBL2815242 0.73 CYP3A4 (0.40) HSD17B10ALOX15MAPK1SMN1; SMN2LMNA
SCHEMBL1828813 0.72 HSPA1A (0.63) HSD17B10ALOX15MAPK1HSPA1APABPC1
SCHEMBL23276528 0.72 STAT3 (0.61) CYP1A2TDP1ALDH1A1
SCHEMBL7686000 0.70 HSPA1A (0.56) HSD17B10ALOX15MAPK1HSPA1APABPC1
SCHEMBL2747203 0.70 CYP3A4 (0.51) HSD17B10SMN1; SMN2LMNAMAPTKDM4E
SCHEMBL5085494 0.69 KCNH2 (0.43) HSD17B10ALOX15SMN1; SMN2LMNAMAPT
SCHEMBL5666941 0.69 KDM4E (0.50) HSD17B10SMN1; SMN2LMNAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2630115-B1 Crosslinking monomers for aliphatic polyamides NEXAM CHEMICAL AB (SE) 2014-05-14 EP claimed
US-20130225769-A1 CROSS-LINKER NEXAM CHEMICAL AB (SE) 2013-08-29 US claimed
US-20140303328-A1 CROSS-LINKER NEXAM CHEMICAL AB (SE) 2014-10-09 US disclosed
US-8772418-B2 Cross-linker NEXAM CHEMICAL AB (SE) 2014-07-08 US disclosed
EP-2630115-B1 Crosslinking monomers for aliphatic polyamides NEXAM CHEMICAL AB (SE) 2014-05-14 EP disclosed
US-20130225769-A1 CROSS-LINKER NEXAM CHEMICAL AB (SE) 2013-08-29 US disclosed
EP-2630115-A1 CROSS-LINKER Nexam Chemical AB (SE) 2013-08-28 EP disclosed
WO-2012052550-A1 CROSS-LINKER NEXAM CHEMICAL AB (SE) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140303328-A1 CROSS-LINKER CAPZA2, PAPSS1, CHIA HSD17B10 3154/4885ALOX15 3582/4885MAPK1 4813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.